{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:58:30Z","timestamp":1785419910490,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2022YFC2009700, 2022YFC2009706"],"award-info":[{"award-number":["2022YFC2009700, 2022YFC2009706"]}]},{"name":"Foundation for Clinical and Translational Medical Research, Central Public Welfare Research of Chinese Academy of Medical Sciences","award":["2019xk320061"],"award-info":[{"award-number":["2019xk320061"]}]},{"name":"Clinical research of central high-level hospitals","award":["2023-GSP-GG-32"],"award-info":[{"award-number":["2023-GSP-GG-32"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05680-5","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:18:28Z","timestamp":1773051508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of serum total bilirubin with recurrent cardiovascular events in patients with in-stent restenosis: a stratified analysis by inflammatory status"],"prefix":"10.1186","volume":"26","author":[{"given":"Miao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Song","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"14","key":"5680_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1056\/NEJMoa035071","volume":"349","author":"JW Moses","year":"2003","unstructured":"Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O\u2019Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"5680_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa032441","volume":"350","author":"GW Stone","year":"2004","unstructured":"Stone GW, Ellis SG, Cox DA, Hermiller J, O\u2019Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221\u201331.","journal-title":"N Engl J Med"},{"issue":"13","key":"5680_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1056\/NEJMoa1607991","volume":"375","author":"KH Bonaa","year":"2016","unstructured":"Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. 2016;375(13):1242\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"5680_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jacc.2022.05.017","volume":"80","author":"G Giustino","year":"2022","unstructured":"Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, et al. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80(4):348\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"10384","key":"5680_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293\u2013301.","journal-title":"Lancet"},{"issue":"16","key":"5680_CR6","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","volume":"61","author":"S Deftereos","year":"2013","unstructured":"Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. 2013;61(16):1679\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"5680_CR7","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/eurheartj\/eht079","volume":"34","author":"F Ribichini","year":"2013","unstructured":"Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, et al. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). Eur Heart J. 2013;34(23):1740\u20138.","journal-title":"Eur Heart J"},{"issue":"11","key":"5680_CR8","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0735-1097(02)02562-7","volume":"40","author":"F Versaci","year":"2002","unstructured":"Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40(11):1935\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"9709","key":"5680_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"C Emerging Risk Factors","year":"2010","unstructured":"Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132\u201340.","journal-title":"Lancet"},{"issue":"2","key":"5680_CR10","doi-asserted-by":"publisher","first-page":"E191","DOI":"10.1152\/ajpendo.00405.2020","volume":"320","author":"JF Creeden","year":"2021","unstructured":"Creeden JF, Gordon DM, Stec DE, Hinds TD. Jr. Bilirubin as a metabolic hormone: the physiological relevance of low levels. Am J Physiol Endocrinol Metab. 2021;320(2):E191\u2013207.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"5680_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.molmed.2023.01.007","volume":"29","author":"L Vitek","year":"2023","unstructured":"Vitek L, Hinds TD Jr., Stec DE, Tiribelli C. The physiology of bilirubin: health and disease equilibrium. Trends Mol Med. 2023;29(4):315\u201328.","journal-title":"Trends Mol Med"},{"key":"5680_CR12","doi-asserted-by":"crossref","unstructured":"Drummond HA, Mitchell ZL, Abraham NG, Stec DE. Targeting Heme Oxygenase-1 in Cardiovascular and Kidney Disease. Antioxid (Basel). 2019;8(6).","DOI":"10.3390\/antiox8060181"},{"issue":"3","key":"5680_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/ATVBAHA.114.304929","volume":"35","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35(3):716\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"5680_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00392-014-0697-z","volume":"103","author":"AA Mahabadi","year":"2014","unstructured":"Mahabadi AA, Lehmann N, Mohlenkamp S, Kalsch H, Bauer M, Schulz R, et al. Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study. Clin Res Cardiol. 2014;103(8):647\u201353.","journal-title":"Clin Res Cardiol"},{"issue":"9","key":"5680_CR15","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139\u2013596.","journal-title":"Circulation"},{"key":"5680_CR16","doi-asserted-by":"crossref","unstructured":"Ryter SW. Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders. Antioxid (Basel). 2022;11(3).","DOI":"10.3390\/antiox11030555"},{"issue":"17","key":"5680_CR17","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351.","journal-title":"Circulation"},{"issue":"18","key":"5680_CR18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1161\/01.CIR.100.18.1872","volume":"100","author":"R Mehran","year":"1999","unstructured":"Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872\u20138.","journal-title":"Circulation"},{"issue":"9994","key":"5680_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0140-6736(15)60657-2","volume":"386","author":"GC Siontis","year":"2015","unstructured":"Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Perez-Vizcayno MJ, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet. 2015;386(9994):655\u201364.","journal-title":"Lancet"},{"issue":"23","key":"5680_CR20","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.jacc.2010.07.028","volume":"56","author":"GD Dangas","year":"2010","unstructured":"Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897\u2013907.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"5680_CR21","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1161\/01.ATV.0000037100.44766.5B","volume":"22","author":"FG Welt","year":"2002","unstructured":"Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"5680_CR22","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/S0735-1097(02)02598-6","volume":"40","author":"IM Chung","year":"2002","unstructured":"Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol. 2002;40(12):2072\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"5680_CR23","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1039\/D5BM00687B","volume":"13","author":"M Yu","year":"2025","unstructured":"Yu M, Dai C, Shi J, Fu J. Immune modulation strategies to reduce in-stent restenosis. Biomater Sci. 2025;13(18):4898\u2013915.","journal-title":"Biomater Sci"},{"issue":"1","key":"5680_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC, Luscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113\u201331.","journal-title":"Eur Heart J"},{"issue":"3","key":"5680_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.carrev.2008.01.003","volume":"9","author":"G Ferrante","year":"2008","unstructured":"Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9(3):156\u201365.","journal-title":"Cardiovasc Revasc Med"},{"issue":"22","key":"5680_CR26","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.jacc.2010.06.045","volume":"56","author":"G Niccoli","year":"2010","unstructured":"Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56(22):1783\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5680_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/0006-2952(95)02395-X","volume":"51","author":"TW Wu","year":"1996","unstructured":"Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51(6):859\u201362.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"5680_CR28","first-page":"e18","volume":"119","author":"CP Soto Conti","year":"2021","unstructured":"Soto Conti CP, Bilirubin. The toxic mechanisms of an antioxidant molecule. Arch Argent Pediatr. 2021;119(1):e18\u201325.","journal-title":"Arch Argent Pediatr"},{"issue":"4","key":"5680_CR29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/HYPERTENSIONAHA.118.11130","volume":"72","author":"TD Hinds Jr","year":"2018","unstructured":"Hinds TD Jr., Stec DE. Bilirubin, a Cardiometabolic Signaling Molecule. Hypertension. 2018;72(4):788\u201395.","journal-title":"Hypertension"},{"issue":"1","key":"5680_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2015.02.051","volume":"240","author":"MK Akboga","year":"2015","unstructured":"Akboga MK, Canpolat U, Sahinarslan A, Alsancak Y, Nurkoc S, Aras D, et al. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015;240(1):110\u20134.","journal-title":"Atherosclerosis"},{"issue":"1","key":"5680_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00011-025-02049-w","volume":"74","author":"Bilirubin metabolism","year":"2025","unstructured":"Bilirubin metabolism. and its application in disease prevention: mechanisms and research advances. Inflamm Res. 2025;74(1):81.","journal-title":"Inflamm Res"},{"issue":"3","key":"5680_CR32","doi-asserted-by":"publisher","first-page":"100431","DOI":"10.1016\/j.cpcardiol.2019.06.003","volume":"46","author":"V Jain","year":"2021","unstructured":"Jain V, Ghosh RK, Bandyopadhyay D, Kondapaneni M, Mondal S, Hajra A, et al. Serum Bilirubin and Coronary Artery Disease: Intricate Relationship, Pathophysiology, and Recent Evidence. Curr Probl Cardiol. 2021;46(3):100431.","journal-title":"Curr Probl Cardiol"},{"issue":"6","key":"5680_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10554-013-0209-7","volume":"29","author":"U Canpolat","year":"2013","unstructured":"Canpolat U, Aytemir K, Yorgun H, Hazirolan T, Kaya EB, Sahiner L, et al. Association of serum total bilirubin levels with the severity, extent and subtypes of coronary atherosclerotic plaques detected by coronary CT angiography. Int J Cardiovasc Imaging. 2013;29(6):1371\u20139.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"5680_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MCA.0000000000000309","volume":"27","author":"KF Zhu","year":"2016","unstructured":"Zhu KF, Wang YM, Wang YQ, Wang NF. The relationship between serum levels of total bilirubin and coronary plaque vulnerability. Coron Artery Dis. 2016;27(1):52\u20138.","journal-title":"Coron Artery Dis"},{"issue":"5","key":"5680_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/15353702-0322805-29","volume":"228","author":"L Novotn\u00fd","year":"2003","unstructured":"Novotn\u00fd L, V\u00edtek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228(5):568\u201371.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"5680_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2169\/internalmedicine.51.6417","volume":"51","author":"T Erdogan","year":"2012","unstructured":"Erdogan T, Cicek Y, Kocaman SA, Canga A, Cetin M, Durakoglugil E, et al. Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion. Intern Med. 2012;51(3):249\u201355.","journal-title":"Intern Med"},{"issue":"1","key":"5680_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/clinchem\/40.1.18","volume":"40","author":"HA Schwertner","year":"1994","unstructured":"Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40(1):18\u201323.","journal-title":"Clin Chem"},{"issue":"1","key":"5680_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2009.02.010","volume":"206","author":"M Tanaka","year":"2009","unstructured":"Tanaka M, Fukui M, Tomiyasu K, Akabame S, Nakano K, Hasegawa G, et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis. 2009;206(1):287\u201391.","journal-title":"Atherosclerosis"},{"issue":"7","key":"5680_CR39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1161\/CIRCULATIONAHA.104.528802","volume":"112","author":"R Ollinger","year":"2005","unstructured":"Ollinger R, Bilban M, Erat A, Froio A, McDaid J, Tyagi S, et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation. 2005;112(7):1030\u20139.","journal-title":"Circulation"},{"issue":"7","key":"5680_CR40","doi-asserted-by":"publisher","first-page":"574","DOI":"10.5551\/jat.6643","volume":"18","author":"T Kuwano","year":"2011","unstructured":"Kuwano T, Miura S, Shirai K, Ike A, Mori K, Shimizu T, et al. Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J Atheroscler Thromb. 2011;18(7):574\u201383.","journal-title":"J Atheroscler Thromb"},{"issue":"7","key":"5680_CR41","doi-asserted-by":"publisher","first-page":"107106","DOI":"10.1016\/j.isci.2023.107106","volume":"26","author":"L Sun","year":"2023","unstructured":"Sun L, Zhao L, Yang K, Li Z, Wang Y, Wang T, et al. Serum total bilirubin and one-year prognosis of patients with coronary artery disease and psoriasis. iScience. 2023;26(7):107106.","journal-title":"iScience"},{"key":"5680_CR42","doi-asserted-by":"crossref","unstructured":"Klein LW, Nathan S, Maehara A, Messenger J, Mintz GS, Ali ZA et al. SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis. J Soc Cardiovasc Angiography Interventions. 2023;2(4).","DOI":"10.1016\/j.jscai.2023.100971"},{"issue":"14","key":"5680_CR43","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jacc.2020.01.056","volume":"75","author":"I Kosmidou","year":"2020","unstructured":"Kosmidou I, Leon MB, Zhang Y, Serruys PW, von Birgelen C, Smits PC, et al. Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020;75(14):1631\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"5680_CR44","doi-asserted-by":"crossref","unstructured":"Zapata-Arriaza E, Aguilar Perez M, Alboniga-Chindurza A, Medina-Rodriguez M, Montaner J, Moniche F et al. Development of a Risk Prediction Nomogram for Carotid Re-Stenosis in the One Year RECAST Registry. Eur J Vasc Endovasc Surg. 2024.","DOI":"10.1016\/j.jvs.2024.08.045"},{"key":"5680_CR45","doi-asserted-by":"crossref","unstructured":"V\u00edtek L, Jir\u00e1skov\u00e1 A, Mal\u00edkov\u00e1 I, Dost\u00e1lov\u00e1 G, Eremi\u00e1\u0161ov\u00e1 L, Danzig V et al. Serum Bilirubin and Markers of Oxidative Stress and Inflammation in a Healthy Population and in Patients with Various Forms of Atherosclerosis. Antioxidants. 2022;11(11).","DOI":"10.3390\/antiox11112118"},{"key":"5680_CR46","doi-asserted-by":"publisher","first-page":"41681","DOI":"10.1038\/srep41681","volume":"7","author":"B Zhu","year":"2017","unstructured":"Zhu B, Wu X, Bi Y, Yang Y. Effect of bilirubin concentration on the risk of diabetic complications: A meta-analysis of epidemiologic studies. Sci Rep. 2017;7:41681.","journal-title":"Sci Rep"},{"issue":"1","key":"5680_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.atherosclerosis.2014.12.042","volume":"239","author":"AR Kundur","year":"2015","unstructured":"Kundur AR, Singh I, Bulmer AC. Bilirubin, platelet activation and heart disease: a missing link to cardiovascular protection in Gilbert\u2019s syndrome? Atherosclerosis. 2015;239(1):73\u201384.","journal-title":"Atherosclerosis"},{"issue":"1","key":"5680_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.diabres.2009.12.022","volume":"88","author":"K Ohnaka","year":"2010","unstructured":"Ohnaka K, Kono S, Inoguchi T, Yin G, Morita M, Adachi M, et al. Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract. 2010;88(1):103\u201310.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05680-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05680-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:02:31Z","timestamp":1776254551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05680-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5680"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05680-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Fuwai Hospital (Approval No.: 2023\u20132076). As this was a retrospective study using anonymized data, the requirement for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No identifying images or personal\/clinical details of individual participants are presented in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"321"}}